activities · 46
what they do
advocacy · 5
- Advocate for increased government funding for cancer research Advocacy for Federal Research FundingPlayed a key role in organizing the 1998 March on Washington that led to legislation doubling the NIH budget over five years and contributed to a 20-fold increase in government funding for prostate cancer research.
- Advocate for increased government research funding Advocacy for Federal Research FundingPlayed a key role in the 1998 March on Washington that led to legislation doubling the NIH budget over five years and contributed to a 20-fold increase in government funding for prostate cancer research.
- Advocates for increased government funding for prostate cancer research Advocacy for Federal Research FundingPlayed a key role in the 1998 March on Washington that led to legislation doubling the NIH budget over five years and has contributed to a 20-fold increase in government funding for prostate cancer research.
- Advocating for Research Funding Advocacy for Federal Research FundingThe organization advocates for increased government funding for prostate cancer research, playing a key role in organizing the 1998 March on Washington which led to legislation doubling the NIH budget and contributing to a 20-fold increase in government funding for prostate cancer research.
- Advocating for increased government research funding Advocacy for Federal Research FundingPlayed a pivotal role in advocacy efforts that led to the doubling of the NIH budget over five years following the 1998 March on Washington and contributed to a 20-fold increase in federal funding for prostate cancer research.
research · 24
- Advancing Prostate Cancer Treatment Development Prostate Cancer Precision Therapy DevelopmentThe organization funds research that has led to significant advancements in prostate cancer treatment, including the development of 14 new therapies, the creation of a genetic map of advanced prostate cancer, and the FDA approval of PARP inhibitors and PSMA-targeted radioligand therapies.
- Conducting Clinical Trials and Genetic Mapping Prostate Cancer Precision Therapy DevelopmentThe organization funds clinical trials for PSMA-targeted radioligand therapies and has created a genetic map of advanced prostate cancer, identifying actionable tumor mutations in over 90% of patients.
- Conducts foundational genomic research on prostate cancer Prostate Cancer Precision Therapy DevelopmentCreated a genetic map of advanced prostate cancer that identified actionable tumor mutations in more than 90 percent of patients, enabling precision oncology advances.
- Convening annual scientific retreats for research disseminationHosts an annual Scientific Retreat that includes scientific presentations, lectures, panel discussions, and poster sessions to share recent research findings; the 2025 retreat featured 49 sessions.
- Fund and conduct prostate cancer research Prostate Cancer Research FundingConducts and funds high-risk, high-reward research to develop effective treatments for prostate cancer, including supporting over 2,615 research projects at 312 cancer centers across 29 countries and investing over $1 billion in research since inception.
- Fund and conduct prostate cancer research Prostate Cancer Research FundingConducts and funds high-risk, high-reward research to develop effective treatments for prostate cancer, including supporting over 2,615 research projects at 312 cancer centers across 29 countries and contributing to a 50% reduction in prostate cancer death rates since the foundation's founding.
- Funding Prostate Cancer Research Prostate Cancer Research FundingThe organization raises and distributes over $1 billion to fund more than 2,615 research projects at 312 cancer centers across 29 countries, focusing on high-risk, high-reward research that has contributed to the development of 14 FDA-approved therapies for prostate cancer.
- Funding prostate cancer research projects globally Prostate Cancer Research FundingFunds high-risk, high-reward prostate cancer research worldwide, having raised over $1 billion to support more than 2,615 research projects at 312 cancer centers across 29 countries.
- Funds prostate cancer research projects globally Prostate Cancer Research FundingHas raised over $1 billion to fund more than 2,615 research projects at 312 cancer centers across 29 countries, supporting high-risk, high-reward research and contributing to major therapeutic advances.
- Host scientific conferences and research dissemination events Scientific Retreats and Researcher ForumsHosts annual scientific retreats featuring scientific presentations, lectures, panel discussions, and poster sessions to share recent prostate cancer research findings; hosted 49 such events at the 32nd Annual Scientific Retreat in 2025.
- Launch large-scale collaborative research initiatives Prostate Cancer Research FundingLaunched the PCF TACTICAL Awards in 2022 to fund large-scale collaborative projects with $5–$10 million over three years, focused on developing advanced therapies for lethal prostate cancer.
- Launch large-scale collaborative research initiatives Prostate Cancer Research FundingLaunched the PCF TACTICAL Awards in 2022 to fund large-scale, multi-institutional collaborative projects with $5–$10 million over three years aimed at developing advanced therapies for lethal prostate cancer.
- Map genetic mutations in advanced prostate cancer Prostate Cancer Precision Therapy DevelopmentFunded research that created a genetic map of advanced prostate cancer, identifying actionable tumor mutations in more than 90% of patients, enabling precision oncology approaches.
- Map genetic profiles of advanced prostate cancer Prostate Cancer Precision Therapy DevelopmentFunded research that created a genetic map of advanced prostate cancer, identifying actionable tumor mutations in more than 90% of patients, enabling precision oncology approaches.
- Mapping the genetic landscape of advanced prostate cancer Prostate Cancer Precision Therapy DevelopmentFunded research that created a comprehensive genetic map of advanced prostate cancer, identifying actionable tumor mutations in more than 90% of patients, enabling precision treatment approaches.
- Partnering with the Department of Veterans Affairs Prostate Cancer Precision Therapy DevelopmentThe organization partners with the Department of Veterans Affairs to prevent, screen, and advance research for prostate cancer among Veterans.
- Reducing prostate cancer mortality through research advances Prostate Cancer Precision Therapy DevelopmentAttributed with reducing the U.S. prostate cancer death rate by 50% since its founding and helping avert approximately 1.5 million prostate cancer deaths globally through supported research advances.
- Support cross-cancer therapeutic breakthroughsProvided significant funding to promising researchers through medical research awards, including support for Dr. Dennis Slamon’s discovery of Herceptin for breast cancer treatment.
- Support development of FDA-approved prostate cancer therapies Prostate Cancer Precision Therapy DevelopmentFunded research that contributed to the development and FDA approval of 14 new prostate cancer therapies, including PARP inhibitors (approved starting in 2020) and the PSMA-targeted radioligand therapy 177lutetium-PSMA-617 (Pluvicto®), approved in March 2022.
- Support development of FDA-approved prostate cancer therapies Prostate Cancer Precision Therapy DevelopmentHas supported the development and FDA approval of 14 new prostate cancer therapies, including PARP inhibitors and the first-in-class PSMA-targeted radioligand therapy 177lutetium-PSMA-617 (Pluvicto®), with ongoing funding for clinical trials testing these therapies across disease states.
- Supporting Collaborative Research Initiatives Prostate Cancer Research FundingThe organization invests in collaborative research initiatives, such as a $45 million consortium of 13 leading cancer centers and the PCF TACTICAL Awards, to accelerate prostate cancer research and develop advanced therapies for lethal prostate cancer.
- Supporting clinical trials of novel prostate cancer therapies Prostate Cancer Precision Therapy DevelopmentCurrently funds clinical trials led by PCF-supported investigators to evaluate PSMA-targeted radioligand therapies across various stages of prostate cancer.
- Supporting development of FDA-approved prostate cancer therapies Prostate Cancer Precision Therapy DevelopmentProvided critical funding that contributed to the development and FDA approval of 14 new prostate cancer treatments, including PARP inhibitors (approved starting in 2020) and the PSMA-targeted radioligand therapy Pluvicto® (approved March 2022).
- Supports development of FDA-approved prostate cancer therapies Prostate Cancer Precision Therapy DevelopmentFunded research that contributed to the development and approval of 14 new prostate cancer therapies, including PARP inhibitors and the PSMA-targeted radioligand therapy 177lutetium-PSMA-617 (Pluvicto®), with ongoing clinical trials in various disease states.
capacity building · 17
- Accelerating large-scale collaborative research initiatives Prostate Cancer Research FundingLaunches and funds large-scale collaborative research programs, such as the TACTICAL Awards (launched in 2022) providing $5–$10 million over three years, and a $45 million investment in a consortium of 13 leading cancer centers to accelerate research and deliver patient outcomes.
- Advancing precision oncology research in Veterans Prostate Cancer Precision Therapy DevelopmentPartners with the Department of Veterans Affairs to advance precision oncology research and treatment, establishing 21 PCF-VA Centers of Excellence focused on prostate cancer prevention, screening, and research among Veterans.
- Establish precision oncology centers of excellence with the VA Prostate Cancer Precision Therapy DevelopmentPartnered with the Department of Veterans Affairs to establish 21 PCF-VA Centers of Excellence (updated from initial 14) focused on advancing precision oncology research and treatment for prostate cancer among Veterans.
- Establishes precision oncology Centers of Excellence with the VA Prostate Cancer Precision Therapy DevelopmentPartnered with the Department of Veterans Affairs to establish 14 (later expanded to 21) PCF-VA Centers of Excellence focused on advancing precision oncology research and treatment for prostate cancer among Veterans.
- Establishing Centers of Excellence Prostate Cancer Precision Therapy DevelopmentThe organization establishes PCF-VA Centers of Excellence, including 21 precision oncology centers, to advance precision oncology research and treatment for prostate cancer, particularly among Veterans.
- Host scientific forums and networking events Scientific Retreats and Researcher ForumsHosts the annual Scientific Retreat featuring scientific presentations, lectures, and panel discussions; facilitates poster sessions and hosts specialized forums such as the Young Investigator Forum and the Gender Equity Networking Initiative (GENI) Forum to support researcher development and collaboration.
- Hosting scientific forums and investigator training programs Scientific Retreats and Researcher ForumsOrganizes annual scientific and professional development forums including the Young Investigator Forum for early-career researchers (2022–2026 cohorts) and the Gender Equity Networking Initiative (GENI) Forum, fostering collaboration and career advancement in prostate cancer research.
- Hosts scientific forums and networking events for researchers Scientific Retreats and Researcher ForumsOrganizes annual events including the Scientific Retreat featuring presentations and panel discussions, the Gender Equity Networking Initiative (GENI) Forum, and the Young Investigator Forum to support collaboration and professional development among funded researchers.
- Invest in collaborative cancer research consortia Prostate Cancer Research FundingInvested over $45 million in a consortium of 13 leading cancer centers to accelerate prostate cancer research and deliver results to patients.
- Invest in collaborative research consortia Prostate Cancer Research FundingInvested over $45 million in a consortium of 13 leading cancer centers to accelerate prostate cancer research and deliver faster results to patients.
- Invests in large-scale collaborative research initiatives Prostate Cancer Research FundingLaunched the PCF TACTICAL Awards in 2022 to provide $5–$10 million over three years for large-scale collaborative projects, and invested over $45 million in a consortium of 13 leading cancer centers to accelerate research and deliver results to patients.
- Organizing Scientific Conferences and Forums Scientific Retreats and Researcher ForumsThe organization hosts scientific events, including annual Scientific Retreats with presentations and poster sessions on prostate cancer research, and forums like the Gender Equity Networking Initiative (GENI) and Young Investigator Forum for researchers.
- Organizing Scientific Conferences and Forums Scientific Retreats and Researcher ForumsThe organization hosts scientific events, including annual Scientific Retreats with presentations and poster sessions on prostate cancer research, the Gender Equity Networking Initiative (GENI) Forum, and the Young Investigator Forum for PCF-funded researchers.
- Partner with the VA to advance prostate cancer research Prostate Cancer Precision Therapy DevelopmentEstablished 21 PCF-VA Centers of Excellence in precision oncology and partners with the Department of Veterans Affairs to prevent, screen, and advance prostate cancer research among Veterans.
- Promote gender equity in cancer research Scientific Retreats and Researcher ForumsOrganizes the annual Gender Equity Networking Initiative (GENI) Forum, with the 11th edition held in 2026, to advance gender equity in the field of cancer research.
- Recruit and support scientific leadershipRecruited Dr. Jonathan Simons as CEO to lead the foundation for fourteen years, strengthening scientific leadership and strategic direction.
- Support early-career prostate cancer researchers Scientific Retreats and Researcher ForumsHosts the Young Investigator Forum for PCF-funded early-career researchers (2022–2026 cohorts) to support professional development and collaboration.
strategies · 55
how they think
Theories of action extracted from this org's own source material. Click any to see the full field of orgs running the same approach.
- Academia-Industry Drug Development Bridge academia-industry partnership modelAccelerates the translation of academic discoveries into real-world therapies by fostering strategic partnerships between academic researchers and pharmaceutical/biotech companies, closing the gap between basic science and clinical application.
- Academia-Industry Partnerships for Drug Development academia-industry partnership modelBy bridging academic research and industry, the foundation accelerates the translation of scientific discoveries into real-world treatments through strategic collaborations with pharmaceutical and biotech companies.
- Academia-Industry Partnerships to Accelerate Drug Development academia-industry partnership modelBridges academic research and industry by collaborating with pharmaceutical and biotech companies to translate scientific discoveries into viable treatments more quickly, leveraging private-sector capabilities in drug development.
- Academia-Industry Research Translation academia-industry partnership modelBridges academic research and pharmaceutical development by fostering partnerships with biotech and drug companies to accelerate the translation of scientific discoveries into new therapies.
- Academia-Industry Translation Bridge academia-industry partnership modelSpeeds the development of new prostate cancer therapies by connecting academic researchers with pharmaceutical and biotech partners to translate basic discoveries into clinical applications and drug development.
- Bridge Academia and Industry for Faster Drug Development academia-industry partnership modelBy facilitating partnerships between academic researchers and pharmaceutical or biotech companies, the foundation accelerates the translation of scientific discoveries into viable treatments and therapies.
- Collaborative Research Acceleration Network collaborative_research_modelFosters a culture of collaboration in prostate cancer research by requiring knowledge sharing, progress reporting, and multi-institutional teamwork, facilitated through mechanisms like the Annual Scientific Retreat and Dream Teams to break down silos and accelerate progress.
- Collaborative Research Culture via Scientific Community Building collaborative_research_networkStrengthens the prostate cancer research field by empowering and connecting scientists across institutions, fostering a collaborative ecosystem that drives collective progress.
- Collaborative Research Network Activation collaborative_research_networkBreaks down silos in prostate cancer research by fostering a connected, collaborative scientific community through structured knowledge sharing, progress reporting, and convenings such as the Annual Scientific Retreat.
- Dream Team Multi-Institution Collaboration Model Dream Team research modelAddresses fundamental challenges in prostate cancer by funding large-scale, interdisciplinary research teams across multiple institutions to tackle complex scientific questions with pooled expertise and resources.
- Dream Team Multi-Institutional Research Model Dream Team research modelFunds large-scale, cross-institutional "Dream Teams" to tackle fundamental challenges in prostate cancer, combining top talent and diverse expertise to drive transformative advances through coordinated, team-based science.
- Education and Research Outreach education_and_research_outreachExpands impact by distributing educational materials and scientific publications, while engaging donors and researchers through targeted outreach to build broader support and awareness.
- Education and Research Outreach for Engagement education_and_research_outreachAdvances awareness and engagement in prostate cancer research by distributing educational materials, scientific publications, and promoting participation among donors and researchers through targeted outreach.
- Education and Research Outreach for Engagement and Dissemination education_and_research_outreachThe foundation promotes awareness and engagement by distributing educational materials, scientific publications, and conducting outreach to donors and researchers to expand the reach and impact of prostate cancer knowledge.
- High-Impact Research Investment with Rigorous Review rigorous research review and fundingIdentifies and funds high-potential research through a rigorous scientific review process, prioritizing projects with the greatest likelihood of advancing prostate cancer biology and treatment development.
- Integrative and Holistic Cancer Care integrative_medicineEnhances conventional prostate cancer treatment by integrating holistic and complementary wellness practices, such as Ayurvedic medicine, to support overall patient well-being.
- Integrative and Holistic Cancer Care Model integrative_medicineEnhances conventional cancer treatment by integrating holistic and complementary wellness practices, such as Ayurvedic medicine, to support overall patient well-being during treatment.
- Integrative and Nutrition-Based Approaches to Cancer Care integrative_medicineThe foundation supports integrative medicine models that combine conventional treatments with holistic practices like Ayurveda and emphasizes nutrition—particularly whole, plant-based diets—as a medical intervention to improve cancer outcomes.
- Integrative and Nutrition-Based Approaches to Cancer Care integrative_medicineSupports integrative medicine by incorporating holistic wellness practices and prioritizing nutrition—such as whole, plant-based diets—as medical interventions alongside conventional cancer treatments to improve patient outcomes.
- Integrative and Nutrition-Based Approaches to Cancer Care integrative_medicineThe foundation supports integrative medicine by incorporating holistic wellness practices and prioritizing nutrition—specifically whole, plant-based foods—as medical interventions that complement conventional cancer treatments.
- Integrative and Nutrition-Based Patient Support integrative_medicineEnhances conventional cancer treatment by integrating holistic wellness practices and prioritizing nutrition—specifically whole, plant-based foods—as a medical intervention to improve patient outcomes.
- Invest in Scientific Talent and Collaboration collaborative_research_modelAccelerates progress by attracting top researchers to the field and requiring collaboration, knowledge sharing, and progress reporting through mechanisms like the Annual Scientific Retreat.
- Invest in Scientific Talent and Collaborative Research Networks collaborative_research_modelThe foundation accelerates progress by investing in top scientific talent and fostering a collaborative research culture—requiring knowledge sharing, progress reporting, and multi-institutional teamwork—through mechanisms like the Annual Scientific Retreat and Dream Teams.
- Invest in Scientific Talent and Collaborative Research Networks collaborative_research_networkAccelerates progress by investing in top scientific talent and fostering a collaborative research culture—through mechanisms like the Annual Scientific Retreat and Dream Teams—that breaks down silos and promotes knowledge sharing across institutions.
- Invest in Scientific Talent and Collaborative Research Networks collaborative_research_modelThe foundation accelerates progress by investing in top scientific talent and fostering a collaborative research culture—requiring knowledge sharing, progress reporting, and multi-institutional cooperation—through mechanisms like the Annual Scientific Retreat and Dream Teams.
- Nutrition as a Therapeutic Intervention nutrition_as_medical_interventionPositions nutrition as a critical component of cancer treatment, advocating for whole, plant-based diets and the elimination of processed foods to improve treatment outcomes and patient health.
- Nutrition as a Therapeutic Intervention nutrition_as_medical_interventionPositions nutrition as a critical component of cancer treatment, advocating for whole, plant-based diets and the elimination of processed foods to improve patient outcomes and support recovery.
- Public-Private Research Partnership Model public-private_research_partnershipAccelerates prostate cancer treatments and cures by partnering with public institutions like the VA to integrate prevention, screening, and research efforts, leveraging shared resources and patient populations for greater impact.
- Public-Private Research Partnership Model public-private_research_partnershipAccelerates prostate cancer treatments and cures by partnering with public institutions like the VA to integrate prevention, screening, and research efforts, leveraging shared resources and infrastructure for broader impact.
- Public-Private Research Partnerships public-private_research_partnershipAccelerates prostate cancer treatments and cures by partnering with public institutions like the VA to integrate prevention, screening, and research efforts, leveraging shared resources and patient populations.
- Public-Private Research Partnerships to Accelerate Cures public-private_research_partnershipPartners with public institutions like the VA to integrate prevention, screening, and research efforts, leveraging shared resources and infrastructure to accelerate treatments and cures for prostate cancer, particularly in high-risk populations such as Veterans.
- Public-Private Research Partnerships to Accelerate Cures public-private_research_partnershipBy partnering with public institutions like the VA, the foundation integrates prevention, screening, and research efforts to accelerate the development of treatments and cures, particularly for high-risk populations such as Veterans.
- Rapid Funding for High-Potential Research rapid_grant_funding_for_high_impact_researchAccelerates discovery by providing rapid and efficient funding to high-potential research projects, removing bureaucratic delays and enabling scientists to move quickly on innovative ideas.
- Rapid, High-Impact Research Funding rapid_grant_funding_for_high_impact_researchAccelerates discovery by providing fast, efficient funding to ambitious, high-potential research projects using a streamlined process that minimizes delays and maximizes scientific momentum.
- Research-Driven Development of Prostate Cancer Treatments research-driven treatment developmentUses scientific research as the foundation for developing effective treatments, ensuring that therapeutic advances are grounded in robust biological understanding and innovation.
- Research-Driven Treatment Development research-driven treatment developmentUses scientific research as the foundation for developing effective prostate cancer treatments, ensuring that clinical advances are grounded in robust biological understanding and innovation.
- Research-Driven Treatment Development research-driven treatment developmentUses rigorous scientific research to drive the development of effective prostate cancer treatments, focusing on understanding cancer biology and translating findings into clinical advances.
- Research-Driven Treatment Innovation research-driven treatment developmentUses cutting-edge research as the foundation for developing effective prostate cancer treatments, ensuring that clinical advances are grounded in robust scientific discovery.
- Rigorous Research Review and Funding for High-Potential Projects rigorous research review and fundingSelects research projects for funding through a rigorous evaluation process focused on scientific merit and potential impact, ensuring resources are directed toward advancing prostate cancer biology and treatment innovation.
- Rigorous Research Review and Funding for High-Potential Projects rigorous research review and fundingThe foundation identifies and funds the most promising research through a rigorous evaluation process, ensuring that resources are directed toward projects with the greatest potential to advance understanding of prostate cancer biology and treatment.
- Rigorous Research Review and Selection rigorous research review and fundingEnsures high-impact outcomes by funding only the most promising research projects, selected through a rigorous evaluation process focused on scientific merit and potential to advance prostate cancer understanding and treatment.
- Rigorous Research Review to Fund High-Potential Projects rigorous research review and fundingHigh-impact research is identified and funded through a rigorous evaluation process that prioritizes scientific merit and potential to advance understanding of prostate cancer biology and treatment.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelAdvances prostate cancer research by applying a holistic funding model that values scientific discovery, human capital, and social impact as interconnected drivers of progress.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelAdvances prostate cancer research by treating funding as an integrated investment in science, people, and societal outcomes, ensuring that financial support drives both discovery and patient-centered impact.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelThe foundation’s funding model integrates scientific rigor with human and social impact considerations, ensuring that research not only advances knowledge but also improves patient outcomes and quality of life.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelUses a holistic funding model that integrates scientific rigor with human and social impact considerations to maximize progress in prostate cancer research and improve patient outcomes.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelAdvances prostate cancer research by investing not only in scientific projects but also in people and the broader social ecosystem of research, creating a holistic engine for sustainable progress and improved patient outcomes.
- Scientific, Human, and Social Investment Framework scientific_human_social_investment_modelThe foundation’s funding strategy is grounded in a holistic model that values scientific discovery, human capital development, and social impact, aiming to accelerate progress and improve patient outcomes through interconnected investments.
- Talent-Driven Research Acceleration invest_in_peopleAccelerates progress by attracting and investing in top scientific talent, recognizing that breakthroughs are driven by exceptional people working at the forefront of prostate cancer research.
- Talent-Driven Research Acceleration invest_in_peopleAccelerates progress in prostate cancer research by attracting and investing in top scientific talent, recognizing that breakthroughs are driven by exceptional individuals.
- Venture Philanthropy Funding Model venture philanthropyApplies a venture philanthropy approach with streamlined applications and 90-day funding decisions to rapidly support high-impact, ambitious research projects, accelerating discovery toward cures.
- Venture Philanthropy Funding Model venture philanthropyApplies a venture philanthropy approach with streamlined applications and 90-day funding approvals to rapidly deploy capital to high-impact, ambitious research projects, accelerating discovery and translation in prostate cancer science.
- Venture Philanthropy Model with Rapid Funding Decisions venture philanthropyThe foundation applies a venture philanthropy approach—streamlining grant applications and committing to 90-day funding approvals—to rapidly deploy capital to high-impact, ambitious research projects that might not receive traditional funding.
- Venture Philanthropy Model with Rapid Funding for High-Impact Research venture philanthropyThe foundation applies a venture philanthropy approach—streamlining applications and enabling funding decisions within 90 days—to rapidly support high-potential, ambitious research projects that aim to transform prostate cancer treatment.
- Venture Philanthropy Model with Rapid Funding for High-Impact Research venture philanthropyApplies a venture philanthropy approach by providing rapid, streamlined grant funding—often within 90 days—to high-potential, ambitious research projects, enabling swift progress toward cures and reducing bureaucratic delays in research advancement.
named programs · 7
what they call their work
Annual Scientific Retreat
Gathering of emerging and established scientists to exchange ideas, collaborate, and connect with industry leaders
Competitive Awards Program
Streamlined funding process with short applications and 90-day approvals to support high-risk, high-reward prostate cancer research projects
PCF Dream Teams
Funds large-scale, multi-institution collaborative research projects to answer fundamental questions in prostate cancer
PCF Global Knowledge Exchange
Platform for the research community to continuously share breakthroughs and address key challenges in prostate cancer research
PCF TACTICAL Awards
Provides $5–$10 million over three years to support large-scale collaborative projects developing advanced therapies for lethal prostate cancer
Prostate Cancer Clinical Trials Consortium
Consortium of 13 leading cancer centers funded by PCF to maintain infrastructure for impactful prostate cancer clinical trials
Young Investigator Program
Provides financial support, leadership opportunities, and mentorship to early-career scientists in prostate cancer research
relationships · 16
who they work with
- Cedars-Sinai Medical Center Partner — Collaborated with Dr. Stuart Holden at Cedars-Sinai Medical Center for prostate cancer treatment and clinical guidance.
- Charity Navigator Government — Rated the Prostate Cancer Foundation with a 100% score and Four-Star Rating.
- Department of Veterans Affairs Partner — Collaborates with PCF on prostate cancer prevention, screening, and research initiatives for Veterans.
- Dream Teams Partner — Multi-institution research collaborations funded by PCF to address fundamental questions in prostate cancer.
- John and Daria Barry Foundation Funder — Provided a $2.5 million gift to establish a Precision Oncology Center of Excellence for U.S. Veterans at the Manhattan VA in partnership with PCF.
- Johns Hopkins Brady Urological Institute Partner — Engaged with specialists at Johns Hopkins Brady Urological Institute, including Dr. Patrick Walsh and Dr. Donald Coffey, for prostate cancer research and treatment insights.
- Legends of Basketball Partner — Partnership on the "Check the Box!" prostate cancer awareness initiative featuring basketball legends promoting PSA screening.
- MD Anderson Cancer Center Partner — Participated in diagnostic evaluations and consultations at MD Anderson Cancer Center, including with Dr. Andy von Eschenbach and Dr. Christopher Logothetis.
- Memorial Sloan Kettering Cancer Center Partner — Consulted with Dr. Howard Scher at Memorial Sloan Kettering Cancer Center for specialized prostate cancer treatment and research guidance.
- Naismith Basketball Hall of Fame Partner — Launched the "Check the Box!" initiative to normalize conversations around prostate health and encourage early detection.
- Novartis Partner — Partnered on the national awareness campaign "Relax, it’s a Blood Test."
- Omni La Costa Partner — Host venue for the PCF Annual Scientific Retreat in 2026.
- Prostate Cancer Clinical Trials Consortium Partner — Collaborative network of 13 leading cancer centers supported by PCF to maintain infrastructure for conducting prostate cancer clinical trials.
- U.S. Department of Veterans Affairs Partner — $65 million public-private partnership to establish PCF-VA Centers of Excellence for precision oncology research and treatment.
- U.S. Department of Veterans Affairs Partner — Co-established 21 PCF-VA precision oncology Centers of Excellence.
- UCLA Partner — Consulted with Dr. David Heber at UCLA for nutritional intervention as part of cancer treatment.